Want to see JP:4882 full AI Analyst Report?
4882 Stock Chart & Stats
¥220.00
-¥14.00(-2.34%)
At close: 4:00 PM EST
¥220.00
-¥14.00(-2.34%)
Day’s Range― - ―
52-Week Range¥134.00 - ¥348.00
Previous CloseN/A
Volume686.20K
Average Volume (3M)734.02K
Market Cap
¥3.35B
Enterprise Value¥1.13K
Total Cash (Recent Filing)¥1.59B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta1.41
Next Earnings
Nov 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-48.09
Shares Outstanding18,429,500
10 Day Avg. Volume1,890,000
30 Day Avg. Volume734,020
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)2.69
Price to Sales (P/S)24.20
P/FCF Ratio-4.95
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-62.5
Revenue Forecast (FY)¥120.00M
Bulls Say, Bears Say
Bulls Say
Sustained Revenue GrowthRevenue has nearly doubled across the reported period, indicating expanding commercial activity and product demand. Continued top-line growth can provide greater operating leverage over time if the company converts scale into narrower losses and stronger cash generation.
Debt-free Balance SheetThe absence of reported debt reduces fixed financial obligations and refinancing exposure, giving management more flexibility while the business develops. Positive equity and substantial assets also provide a stronger balance-sheet foundation than a similarly loss-making company with significant leverage.
Strong Gross ProfitabilityStrong gross profitability suggests the company retains meaningful value from each unit of revenue before operating expenses. That underlying economics may support future margin improvement if operating costs become more disciplined and revenue growth continues at scale.
Bears Say
Persistent Operating LossesLarge recurring operating and net losses show that revenue growth has not yet translated into a sustainable earnings model. Even with improvement in 2026, continued losses can consume equity, restrict investment capacity, and delay the point at which the business funds itself.
Ongoing Cash BurnPersistent negative operating and free cash flow means the company is consuming cash to run the business rather than generating internal funding. The recent reduction in burn is encouraging, but substantial ongoing outflows could require external funding unless losses narrow materially.
Material Equity ErosionThe substantial decline in equity indicates that accumulated losses have reduced the resources attributable to shareholders over time. Continued erosion would weaken financial resilience and could limit the company’s ability to absorb execution setbacks while funding future development.
Perseus Proteomics, Inc. News
4882 FAQ
What was Perseus Proteomics, Inc.’s price range in the past 12 months?
Perseus Proteomics, Inc. lowest stock price was ¥134.00 and its highest was ¥348.00 in the past 12 months.
What is Perseus Proteomics, Inc.’s market cap?
Perseus Proteomics, Inc.’s market cap is ¥3.35B.
When is Perseus Proteomics, Inc.’s upcoming earnings report date?
Perseus Proteomics, Inc.’s upcoming earnings report date is Nov 12, 2026 which is in 52 days.
How were Perseus Proteomics, Inc.’s earnings last quarter?
Perseus Proteomics, Inc. released its earnings results on Aug 13, 2026. The company reported -¥11.85 earnings per share for the quarter.
Is Perseus Proteomics, Inc. overvalued?
According to Wall Street analysts Perseus Proteomics, Inc.’s price is currently Overvalued.
Does Perseus Proteomics, Inc. pay dividends?
Perseus Proteomics, Inc. does not currently pay dividends.
What is Perseus Proteomics, Inc.’s EPS estimate?
Perseus Proteomics, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Perseus Proteomics, Inc. have?
Perseus Proteomics, Inc. has 18,429,500 shares outstanding.
What happened to Perseus Proteomics, Inc.’s price movement after its last earnings report?
Perseus Proteomics, Inc. reported an EPS of -¥11.85 in its last earnings report. Following the earnings report the stock price went up 2.797%.
Which hedge fund is a major shareholder of Perseus Proteomics, Inc.?
Currently, no hedge funds are holding shares in JP:4882
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Perseus Proteomics, Inc.
Based in Tokyo, Japan, Perseus Proteomics Inc. operates as a biotechnology venture specializing in the development of antibody-based therapeutics for various ailments, including cancer. Its core operations encompass pioneering antibody discovery, alongside providing extensive research support services. These services include hybridoma antibody sequencing, the production of antibody proteins, and undertaking contract antibody research projects. Furthermore, Perseus Proteomics supplies its own antibody products to the market. The company boasts a robust development pipeline featuring several promising candidates: PPMX-T001, an antibody targeting hepatocarcinoma; PPMX-T002, an oncology therapeutic; PPMX-T003, designed for the treatment of adult T-cell leukemia/lymphoma; and PPMX-T004, an innovative antibody-drug conjugate. Established in 2001, the firm maintains its headquarters in the Japanese capital.
Technical Analysis
Trans Genic Inc.
―
Cosmo Bio Co., Ltd.
―
ReproCELL Inc.
―
Human Metabolome Technologies, Inc.
―
Precision System Science Co.,Ltd
―